Astragaloside IV and Saponins of Rhizoma Polygonati Cure Cyclophosphamide-Induced Myelosuppression in Lung Adenocarcinoma via Down-Regulating miR-142-3p

Xian Gu, Ling-yu Zhu, Zhen-ye Xu* and Ke-ping Shen*

Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Our previous study revealed that Shuanghuang Shengbai granule could cure the myelosuppression induced by cyclophosphamide (CTX) in lung cancer. However, its hematopoietic effects and molecular mechanisms remain not fully understood. Therefore, this study was intended to investigate the effects and the underlying mechanisms of Astragaloside IV (AS) and saponins of rhizoma polygonati (SRP), the two main bioactive ingredients of Shuanghuang Shengbai granule, on CTX-induced myelosuppression. CTX inhibited the proliferation and promoted apoptosis in bone marrow hematopoietic stem cells (BMHSCs), accompanied by the increased expression of miR-142-3p. AS and/or SRP treatment could alleviate CTX-induced cell injury and suppress the expression of miR-142-3p. Over-expression of miR-142-3p partially reversed the therapeutic effect of AS and/or SRP on CTX-induced cell injury in BMHSCs. Further mechanism exploration discovered that HMGB1 was the target gene of miR-142-3p, and miR-142-3p negatively regulated the expression of HMGB1. To further explore the function of AS and/or SRP in vivo, we constructed a lung cancer xenograft combined with CTX-induced myelosuppression mouse model, and we found that AS and SRP remarkably reversed the CTX-induced reduction of white blood cells, bone marrow nucleated cells, and thymus index in vivo and did not affect the chemotherapy effect of lung cancer. Collectively, our results strongly suggested that AS and SRP could improve the hematopoietic function of myelosuppressed lung cancer mice, and their effects may be related to the inhibition of miR-142-3p expression in BMHSCs.

Keywords: astragaloside IV, saponins of rhizoma polygonati, mir-142-3p, myelosuppression, HMGB1

INTRODUCTION

Lung cancer is the most common malignant tumor that causes the highest number of cancer-related death worldwide (1). Although significant progress has been made in the treatment strategies of lung cancer, the 5-year survival rate of lung cancer patients is still <20%, according to the latest epidemiological survey (2). Chemotherapy is the most effective systemic treatment for lung
cancer (3). However, myelosuppression often occurs during chemotherapy for lung cancer patients (4). Chemotherapy-induced myelosuppression, which is often manifested as a decline in white blood cells (WBCs) and a series of hematopoietic dysfunction, is a main obstacle that restricts the progress of chemotherapy (5, 6). Therefore, it is important to improve the symptoms of myelosuppression for the insurance of the efficacy of chemotherapy. At present, drugs such as recombinant human granulocyte colony stimulating factor (G-CSF), erythropoietin (EPO), and thrombopoietin (TPO), which can protect bone marrow function and promote the recovery of hematopoietic function, are often added in the sequential therapy of conventional chemotherapy regimens (7, 8). EPO and TPO are expensive, while G-CSF has a potential safety hazard (potential role in promoting tumor cell proliferation) (9). Therefore, it is urgent to find inexpensive, safe, and effective drugs to ameliorate chemotherapy-induced myelosuppression.

Traditional Chinese medicine has increasingly been studied and used as a novel adjunctive treatment in different cancers (10). Shuanghuang Shengbai granule has been applied in cancer treatment for decades (11). According to our previous studies (12, 13), it had an ability to increase WBC recovery and alleviate myelosuppression during chemotherapy. Reportedly (13), WBCs were mainly differentiated from bone marrow hematopoietic stem cells (BMHSCs), and Shuanghuang Shengbai granule could promote the proliferation of CD34+SCA1+ BMHSCs via regulation of microRNAs. The results suggested that some bioactive ingredients of Shuanghuang Shengbai granule could inhibit BMHSC injury during chemotherapy, and screening these bioactive ingredients may provide a basis for the development of anti-myelosuppression drugs in the future.

Based on all these backgrounds and our previous studies, our present study focused on Astragaloside IV (AS) and saponins of rhizoma polygonati (SRP), the two main bioactive ingredients of Shuanghuang Shengbai granule, in bone marrow hematopoietic function and their underlying mechanisms and further exploring on whether these two bioactive ingredients could cure myelosuppression in a CTX-induced myelosuppression mouse model.

**MATERIALS AND METHODS**

**Animals and Isolation of BMHSCs**

Male BALB/c nude mice (6-week-old, weighing 20 ± 2 g) were purchased from Vital River Laboratories (Jiaxing, Zhejiang, China) and maintained in the specific-pathogen-free animal laboratory of Longhua Hospital (Shanghai, China) under controlled environmental conditions. All of the animal experiments and procedures were approved by the IACUC of Longhua Hospital. After being sacrificed, the femur and tibia of the mice were harvested. Then, bone marrow cells (BMCS) were flushed from the bones before adding 2 ml hemolysin (Sigma-Aldrich, St. Louis, MO, USA) to damage the red blood cells to form a single-cell suspension. The CD34+SCA1+ BMHSCs were isolated from BMCS by using a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) according to the manufacturers’ standard protocols (BioLegend, San Diego, CA, USA) as previously described (13). Data was analyzed by Flowjo software (Tree Star, San Diego, CA, USA).

**Cell Culture and miRNA Transfection**

BMHSCs were cultured in StemSpan serum-free expansion medium (StemCell Technologies, Vancouver, BC, Canada) supplemented with 50 ng/ml stem cell factor (eBioscience, San Diego, CA, USA) and 50 ng/ml fibroblast growth factor-1 (PeproTech, Rocky Hill, NJ, USA) in a humidified atmosphere of 5% CO2 at 37°C. When the cells were in logarithmic phase, the cells were collected for transfection.

The miR-142-3p mimics (142-3p) and corresponding negative control (NC) were synthesized and purchased from GenePharma Company (Shanghai, China). The full length of HMGB1 was subcloned into pcDNA3.1 vector to overexpress HMGBl (HMGBl), and empty pcDNA3.1 as negative control (pcDNA) was purchased from GenePharma Company. Transfection was performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

**CK-8 Assay**

Cell viability was measured by using a Cell Counting-8 kit (CCK-8, Dojindo, Kumamoto, Japan). BMHSCs (5.0 × 10⁷/well) were seeded in 96-well microtiter plates (Corning Costar, NY, USA). After the indicated treatment, the CCK-8 solution (10 µl/well) was added into the wells and incubated for 2 h according to the manufacturer’s protocol. Cell viability was reflected by measuring the absorbance of the converted dye at 450 nm with a microplate reader (Bio-rad, Hercules, CA, USA).

**BrdU Assay**

Cell proliferation was measured by BrdU incorporation assay (Roche Applied Science, Germany). BMHSCs (5.0 × 10³/well) were plated in 96-well microtiter plates (Corning Costar). After the indicated treatment, the BrdU solution (10 µl/well) was added into the wells and incubated for 2 h. Then, the cells were fixed and denatured with FixDenat solution for 30 min incubated with anti-BrdU monoclonal antibody for 1.5 h and tetramethylbenzidine substrate for 15 min according to the manufacturer’s protocol. Cell proliferation was reflected by measuring the absorbance of the converted dye at 450 nm with a microplate reader (Bio-rad).

**Annexin V-PI Staining Assay**

Cell apoptosis was measured using Annexin V/PI staining assay as described previously (14). After the indicated treatment, BMHSCs were harvested and washed twice in PBS. Then, Annexin V-FITC and PI reagents were added into the cell suspension according to the manufacturer’s instruction (KeyGen, Nanjing, Jiangsu, China). Each sample was quantitatively analyzed at Em = 488 nm and Ex = 570 nm by using a FACSCanto II flow cytomter (BD Biosciences), and then the
fluorescence of each sample was analyzed by using the CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA).

**Luciferase Reporter Assay**

The putative miR-142-3p binding site in the 3′UTR of HMGB1 was predicted by miRanda (http://www.microrna.org/microrna/home.do). The 3′UTR of HMGB1 containing the wild-type or mutant miR-142-3p binding site was constructed and ligated into pGL3 plasmid (Invitrogon) according to the manufacturer’s instruction. Cells were co-transfected with or mutant miR-142-3p binding site was constructed and quantifying the expression of miR-142-3p and HMGB1, U6 and GAPDH were used as internal controls for normalizing the relative luciferase activities were detected by a dual-luciferase reporter assay system (Promega, Madison, WI, USA) according to the manufacturer’s instruction. Renilla luciferase was used for normalization.

**Real-Time Quantitative PCR**

RNA was extracted from cells using Trizol Reagent (Invitrogon) and reversed transcriptase into cDNA by using a Prime Script RT reagent kit (TaKaRa, Dalian, China). Then, real-time quantitative PCR (RT-qPCR) was performed in triplicate using SYBR Premix Ex Taq Kit (Takara) according to the manufacturer’s instruction. U6 and GAPDH were used as internal controls for normalizing and quantifying the expression of miR-142-3p and HMGB1, respectively. The relative expression levels of miR-142-3p and HMGB1 were calculated by using the 2−ΔΔCT method. The primer sequences for miR-142-3p were 5′-GTCGTATCCAGTGAGGCGGAG-3′ (forward) and 5′-GTCGTATCCAGTGAGGCGGAG-3′ (reverse). The primer sequences for HMGB1 mRNA were 5′-GATGGGCAAAGGAGATCCTA-3′ (forward) and 5′-CTTGGGGTCTCCTTTTGGGG-3′ (reverse).

**Western Blot Analysis**

Proteins were extracted by RIPA buffer (Sigma-Aldrich) containing 1% protease inhibitor (cocktail, CalbioChem, Darmstadt, Germany), and the concentration of proteins was determined by using a BCA Protein Assay Kit (Beyotime, Shanghai, China). Equal amounts of proteins (70 µg proteins per sample) were denatured at 95°C for 5 min and then separated by SDS-PAGE system (Bio-rad). After transferring the electrophoretic protein onto PVDF membranes (Millipore, Billerica, MA, USA) by electrotransfer (Bio-rad) and blocking with 5% non-fat milk at room temperature for 90 min, the proteins were probed with primary antibodies against Bcl-2 (ab196495), Bax (ab216494), cleaved caspase3 (c-cas3, ab214430), caspase3 (cas3, ab13847), HMGB1 (ab18256), and GAPDH (ab181602) (Abcam, Cambridge, MA, USA) at 4°C overnight, followed by incubation with the appropriate peroxidase-conjugated secondary antibodies at room temperature for 1 h. Blots were developed by chemiluminescence (Beyotime), and then an X-ray film was scanned. The gray ratios of the target protein bands were accurately determined by an Image-J analysis system (NIH, Rockville Pike, Bethesda, MD, USA).

**Animal Model**

Lung cancer xenograft model was constructed with A549 cell inoculation according to our previous research (13). When the tumor volume was about 200 mm³ [measured with a vernier caliper, the tumor volume was calculated as described previously (13)], then mice with similar tumor size were selected and randomly divided into control group (Ctrl) (n = 10 mice), CTX group (model) (n = 10 mice), CTX + AS group (n = 10 mice), CTX + SRP group (n = 10 mice), and CTX + AS + SRP group (n = 5 mice). CTX (Jiangsu Hengrui Medicine Co. Ltd, Jiangsu, China) was used to establish a myelosuppression mouse model. AS and SRP were obtained from the drug preparation center of Longhua Hospital. The mice in the CTX model group were given CTX (30 mg/kg/d) intraperitoneally (i.p.) for 14 days, and the control group received an equal volume of saline. The treatment groups were i.p. injected with AS (20 mg/kg/day), SRP (40 mg/kg/day), or AS (20 mg/kg/day) + SRP (40 mg/kg/day) for 14 days at 24 h after CTX administration. The mice were sacrificed, and their BMCs were collected for further analysis.

**Determination of Bone Marrow Hematopoietic Function**

We investigated the effects of AS and SRP on bone marrow hematopoietic function, including peripheral blood, bone marrow nucleated cells (BMNCs) count, and thymus/spleen indexes in mice.

For general blood indexes detection, all mice’s peripheral blood was collected from the eye socket vein. Then, WBCs, red blood cells (RBCs), and platelets (PLTs) were counted with an automatic blood cell analyzer (DxH 800TM, Beckman Coulter, Miami, FL, USA).

For BMNCs count, RBCs in BMC suspension were damaged with hemolysin and then centrifuged for 15 min at 2,000 rpm. The BMNCs were removed and washed with sterile PBS and then suspended and counted with an inverted optical microscope (CX43, Olympus, Tokyo, Japan).

For determination of thymus/spleen indexes, the mice were sacrificed, and then the thymus and spleen were obtained and weighed: thymus index = thymus weight/body weight; spleen index = spleen weight/body weight.

**Statistical Analysis**

Data were expressed as means ± SD (standard deviation). The data were assessed using one-way ANOVA (post hoc test: LSD). Statistical analysis was performed by GraphPad Prism software (La Jolla, CA, USA). P <0.05 was considered a statistically significant difference.

**RESULTS**

**AS and SRP Alleviated CTX-Induced Cell Injury in BMHSCs**

At first, we examined the effect of CTX, AS, or SRP treatment alone on cell viability in BMHSCs. The results (Figures 1A–C) showed that, after treatment with CTX, AS, or SRP at a concentration range from 0 to 40 µM for 48 h, CTX inhibited
FIGURE 1 | Astragaloside IV (AS) and saponins of rhizoma polygonati (SRP) alleviated cyclophosphamide (CTX)-induced cell injury in bone marrow hematopoietic stem cells (BMHSCs). BMHSCs were treated with CTX, AS, or SRP at various concentrations that range from 0 to 40 µM, 20 µM CTX + 5 µM AS, or 20 µM CTX + 10 µM SRP for 48 h. (A–D) Cell viability was measured by CCK-8 assay. (E) Cell proliferation was measured by BrdU assay. (F) Apoptosis was detected by Annexin V-PI staining. (G) Protein expressions of Bcl-2, Bax, and c-cas3/cas3 were determined by Western blot. *P < 0.05, **P < 0.01 vs. Ctrl group; #P < 0.01 vs. CTX-alone group; †P < 0.05 vs. CTX + AS + SRP group; n = 6.

cell viability in a concentration-dependent manner, while AS or SRP treatment alone had no harmful effect on it in BMHSCs. We next investigated whether AS and SRP could alleviate CTX-induced cell injury in BMHSCs. As shown in Figures 1D–F, AS and SRP could inhibit CTX-induced cell viability reduction, proliferation attenuation, and apoptosis. In addition, AS combined with SRP had an obvious synergistic protective effect in BMHSCs. Moreover, AS and SRP did not affect the killing effect of CTX in A549 cells (Supplementary Figure 1). We further investigated the effect of AS and SRP on the expressions of CTX-induced apoptosis-related proteins. The Western blot results illustrated that AS and SRP triggered a rise of Bcl-2 and a decline of Bax and cleaved caspase-3 under CTX condition (Figure 1G). All the data suggested that AS and SRP may be the potential anti-myelosuppression drugs during chemotherapy.

AS and SRP Prevented CTX-Induced Cell Injury Through Down-Regulation of miR-142-3p in BMHSCs

Our previous study indicated that Shuanghuang Shengbai granule could reverse the up-regulation of miR-142-3p induced by CTX (13). We hypothesized that AS and SRP could interact with miR-142-3p in BMHSCs, and the RT-qPCR results disclosed that CTX augmented miR-142-3p expression in BMHSCs, which was consistent with our previous findings, while both AS and SRP partially reversed the effects of CTX on miR-142-3p expression (Figure 2A). Hence, we speculated that miR-142-3p
expression may be involved in AS and SRP preventing CTX-induced cell injury in BMHSCs. To investigate the potential interaction among miR-142-3p expression, AS, SRP, and CTX-induced cell injury in BMHSCs, we examined the role of miR-142-3p over-expression in it. As shown in Figure 2B, miR-142-3p level was enhanced after transfection of miR-142-3p mimic. In the CTX-induced cell injury model, over-expression of miR-142-3p could reverse the protective effect of AS and SRP on BMHSCs by inhibiting cell proliferation (Figures 2D,E) and promoting apoptosis (Figures 2D,E). The phenomenon was also verified by Western blot. Compared to CTX + AS + NC group, CTX + SRP + NC group, or CTX + AS + SRP + NC group, over-expression of miR-142-3p induced the drop of Bcl-2 protein level and the rise of Bax and caspase-3 protein level (Figure 2F).

**MiR-142-3p Directly Targeted HMGB1 in BMHSCs**

Based on miRanda, we identified a putative miR-142-3p binding site in the 3'UTR of HMGB1 (Figure 3A). Then, our RT-qPCR and Western blot results found that miR-142-3p
transfection could significantly decrease HMGB1 mRNA and protein expression in BMHSCs (Figures 3B, C). Moreover, dual-luciferase reporter assays also showed that co-transfection of miR-142-3p with the wild-type 3′UTR led to a 55% loss of luciferase reporter activity (Figure 3D); however, mutation of the miR-142-3p binding site in the HMGB1 3′UTR abolished the effect of miR-142-3p (Figure 3D), which indicated that miR-142-3p negatively regulates HMGB1 in BMHSCs by directly targeting the 3′UTR of HMGB1.

**Over-expression of HMGB1 Reversed the Functional Roles of miR-142-3p**

To further confirm that over-expression of miR-142-3p inhibited the therapeutic effect of AS and SRP on CTX-induced cell injury in BMHSCs through a HMGB1-dependent mechanism, we conducted functional rescue assay. Our data showed that, compared with miR-142-3p mimics + pcDNA3.1 vector group, the expression of HMGB1 was dramatically increased after co-transfection of miR-142-3p mimics and pcDNA-HMGB1 vector in BMHSCs (Figures 4A, B). The Annexin V-PI staining results showed that the promotion effect of miR-142-3p on apoptosis was reversed by pcDNA-HMGB1 vector transfection in BMHSCs under CTX + AS or CTX + SRP condition (Figures 4C, D). At the same time, the expressions of Bax and cleaved caspase3 were decreased, and the expression of Bcl-2 was increased in miR-142-3p-overexpressed BMHSCs after exogenous up-regulation of HMGB1 under CTX + AS or CTX + SRP condition (Figures 4E, F). Therefore, our data clearly confirmed that over-expression of miR-142-3p promoted apoptosis in BMHSCs by directly targeting HMGB1 under CTX + AS or CTX + SRP condition.

**AS and SRP Cure Myelosuppression in vivo**

To further explore the function of AS and/or SRP in vivo, we constructed a lung cancer xenograft combined with a CTX-induced myelosuppression mouse model. Although AS and/or SRP did not affect the efficacy of CTX chemotherapy (compared with CTX-alone group, the tumor mass in CTX + AS, CTX + SRP, and CTX + AS + SRP groups was not changed significantly (Figure 5A)), they could alleviate the reduction of WBCs (Table 1) and BMNCs (Figure 5B) caused by CTX chemotherapy. In addition, we examined the thymus/spleen indexes in all the groups, and the data showed that, compared with the control group, the thymus index was decreased, and the thymus index was increased in CTX groups. Compared with the CTX-alone group, both AS and SRP remarkably increased the thymus index, while their effects on spleen index were not significant (Figures 5C, D). We also examined the expressions of miR-142-3p and HMGB1 in BMHSCs isolated from the mice in these groups, and the RT-qPCR and Western blot results showed that, compared with the CTX-alone group, the expression of miR-142-3p was significantly decreased, and the mRNA and protein expression of HMGB1 were significantly increased in the CTX + AS, CTX + SRP, and CTX + AS + SRP groups (Supplementary Figure 2). All the data suggested that AS and/or SRP could cure myelosuppression after CTX chemotherapy, and the effects may be related to their actions in regulating miR-142-3p and HMGB1 expressions in BMHSCs.

**DISCUSSION**

At present, chemotherapy is still a relatively effective and widely used treatment strategy for malignant tumors. However, due to the serious multi-system toxic and side effects of chemotherapy drugs, it may lead to the decline of immune function and bone marrow hematopoietic dysfunction, thus leading to the interruption of chemotherapy (5, 6). The currently used anti-myelosuppression drugs are expensive and do not work as well as expected (7–9), so it is very necessary to find inexpensive, safe, and effective anti-myelosuppression drugs.

CTX is a broad-spectrum anti-tumor drug that has inhibitory effects on a variety of tumors including lung cancer (15, 16). The most common side effect of CTX is myelosuppression (16). WBC reduction of peripheral blood is the main clinical manifestation of chemotherapy-induced myelosuppression (13, 17). The main source of WBCs is differentiation of BMHSCs (13). Therefore, BMHSC injury can cause myelosuppression. According to our previous studies (12, 13), we investigated the effect of AS and/or SRP on CTX-induced myelosuppression in vitro, and our findings showed that they could alleviate CTX-induced cell injury in BMHSCs. As a consequence of the number of BMNCs, a direct indicator of bone marrow hematopoietic function, high BMNC content generally represents strong hematopoietic function (18).
Over-expression of HMGB1 reversed the effect of miR-142-3p on apoptosis in bone marrow hematopoietic stem cells. (A,B) After co-transfection with miR-142-3p mimic and pcDNA-HMGB1, HMGB1 mRNA and protein levels were determined by RT-qPCR and Western blot, respectively. (C,D) Cell apoptosis was detected by Annexin V-PI staining under CTX + AS (C) or CTX + SRP (D) condition. (E,F) Protein expressions of Bcl-2, Bax, and c-cas3/cas3 were determined by Western blot. Cell apoptosis was detected by Annexin V-PI staining under CTX + AS (E) or CTX + SRP (F) condition. *P < 0.05 vs. NC + pcDNA group; #P < 0.05 vs. 142-3p + pcDNA group; n = 6.
The expression of anti-apoptotic factor Bcl-2 can activate the cleavage of caspase3 and induce apoptosis (in vivo) after chemotherapy (8). Thymus index is one of the important indexes of cellular immunity, and it is closely related to hematopoietic function (9). Therefore, we further examined these indicators to evaluate the anti-myelosuppression and hematopoietic effects of AS and/or SRP in lung cancer xenograft combined with CTX-induced myelosuppression mice. As a result, AS and/or SRP reversed the CTX-induced reduction of WBCs, BMNCs, and thymus index in vivo and, at the same time, did not affect the efficacy of CTX chemotherapy in vitro and in vivo. Collectively, these results expounded that AS and SRP could improve myelosuppression and hematopoietic function, and they may be the prospective anti-myelosuppression drugs during chemotherapy.

We next investigated why could AS and/or SRP inhibit CTX-induced myelosuppression. It is well-known that the increased expression of pro-apoptotic factor Bax and the decreased expression of anti-apoptotic factor Bcl-2 can activate the cleavage of caspase3 and induce apoptosis (10). In the present study, CTX induced BMHSC apoptosis by down-regulation of Bcl-2 and up-regulation of Bax, with activation of caspase3. This result was consistent with the fact that CTX causes myelosuppression (11). We observed that AS and/or SRP could partially reverse the effect of CTX on the expression of the molecules mentioned above, suggesting that As and SRP inhibited CTX-induced BMHSC injury by triggering the increase of Bcl-2 and the decrease of Bax and cleaved caspase-3.

We further investigated how AS and/or SRP affects the expressions of apoptosis-related proteins and prevent CTX-induced cell injury in BMHSCs. Based on our previous results (12), we hypothesized that miR-142-3p expression may be involved in this study. As we have predicted, both AS and SRP reversed the CTX-induced up-regulation of miR-142-3p expression. There was an evidence that miR-142-3p accelerated cell apoptosis in non-small cell lung cancer cells by down-regulation of miR-142-3p. Therefore, we further examined how AS and/or SRP affects the inhibitory effect of AS and/or SRP on CTX-induced apoptosis of BMHSCs. Based on our previous results (13), we hypothesized that miR-142-3p expression may be involved in this study. As we have predicted, both AS and SRP reversed the CTX-induced up-regulation of miR-142-3p expression. There was an evidence that miR-142-3p accelerated cell apoptosis in non-small cell lung cancer cells by down-regulation of miR-142-3p. Therefore, we further examined how AS and/or SRP affects the inhibitory effect of AS and/or SRP on CTX-induced apoptosis of BMHSCs. It hinted that AS and SRP alleviated CTX-induced cell injury in BMHSC via down-regulation of miR-142-3p.

miRNAs play biological roles by negatively regulating target genes (14). Through the target gene prediction software, we found that miR-142-3p and the HMGB1 3′-UTR region had the complementary base pairing binding sequence. HMGB1 has been shown to be involved in regulating cell survival and death mainly through DNA repair pathways (15–17). Xiao et al. reported that miR-142-3p inhibited cell proliferation and induced cell apoptosis in non-small cell lung cancer cells by targeting HMGB1 (18). We further confirmed that miR-142-3p directly targeted HMGB1 by RT-qPCR, Western blot, and luciferase reporter assay. Importantly, we also showed that the miR-142-3p overexpression-induced apoptosis in BMHSCs was partly reversed by up-regulating HMGB1 expression under CTX + AS or CTX + SRP condition.

Collectively, our data demonstrated that AS and SRP alleviated CTX-induced cell injury in BMHSCs via up-regulation of HMGB1 through inhibition of miR-142-3p, improved the hematopoietic function, and cured myelosuppression in CTX-induced myelosuppression mice.

### DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
**AUTHOR CONTRIBUTIONS**

XG performed the experiments and drafted the manuscript. Z.-yX and K.-pS participated in the design of this study. L.-yZ performed the statistical analysis. K.-pS participated in scientific discussion of the data and reviewed the manuscript.

**REFERENCES**

1. Romaszko AM, Doboszyńska A. Multiple primary lung cancer: a literature review. Adv Clin Exp Med. (2018) 27:725–30. doi: 10.17219/acem/68631
2. Abdelhamid K, Kakourou A, Degrauwe N, Nikolopoulou A, Bouchaab H, Peters S, et al. Small-cell lung cancer: management and novelties. Rev Mod Suis. (2020) 16:1079–85.
3. Rossi A, Tay R, Chiramel I, Prealj A, Califano R. Current and future therapeutic approaches for the treatment of small cell lung cancer. Expert Rev Anticancer Ther. (2018) 18:473–86. doi: 10.1586/14737390.2018.1453611
4. Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. (2020) 28:925–32. doi: 10.1007/s00520-019-04875-1
5. Genova C, Rijavec E, Grossi F. Hematopoietic growth factors in lung cancer. Curr Oncol Pract. (2016) 28:135–44. doi: 10.1007/CO.0000000000002628
6. Epstein RS, Aapro MS, Rasu Roy UK, Salimi T, Krentsky J, Leone-Perkins ML, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors. Adv Ther. (2020) 37:3606–18. doi: 10.1007/s12325-020-01419-6
7. Sexton Ward A, Kabiri M, Yuceil A, Silverstein AR, van Eijndhoven E, Bowers C, et al. The long-term social value of granulocyte colony-stimulating factors. Am J Manag Care. (2019) 25:886–93.
8. Tunceli O, Bailey RA, Stephenson JJ, Singer J. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy. J Oncol Pharm Pract. (2019) 13:305–14. doi: 10.1177/1078155212466137
9. Fan Z, Li Y, Zhao Q, Fan L, Tan B, Zuo J, et al. Highly expressed granulocyte colony-stimulating factor (G-CSF) and granulocyte-colony stimulating factor receptor (G-CSFR) in human gastric cancer leads to poor survival. Med Sci Monit. (2018) 24:1701–11. doi: 10.12659/msm.909128
10. Ding ZJ, Xu DQ, Lao YZ, Xu HX. Interactions between Traditional Chinese Medicine and anticancer drugs in chemotherapy. World J Tradit Chin Med. (2017) 3:38–45. doi: 10.4103/wtcm.wtcm_6_17
11. Gu X, Xu ZY, Zhu LY, Wang LF, Li K, Pei Q. Dual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophosphamide-induced myelosuppression. Oncotargets Ther. (2013) 6:199–209. doi: 10.2147/OTT.S37407
12. Wang LF, Xu ZY, Wang QZ, Zhang M, Yan GY, Hou AJ, et al. Clinical observation of Shuanghuang Shengbai Granule on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients. Chin J Integr Med. (2017) 23:105–9. doi: 10.1007/s11655-016-2503-0
13. Wang S, Xu Z, Wang L. Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNA. Oncotarget. (2017) 8:62154–66. doi: 10.18632/oncotarget.19129
14. Yang X, Zhang J, Ji Q, Wang F, Song M, Li Y. Autophagy protects MCT3-E1 cells upon aluminum-induced apoptosis. Biol Trace Elem Res. (2018) 185:433–9. doi: 10.1007/s11181-018-1264-7
15. Villa M, Attianese D, Petracchini M, Ferrero A. Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient. Anticancer Drugs. (2019) 30:964–8. doi: 10.1097/CAD.0000000000000815
16. Li D, He S. Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer. Int J Clin Exp Pathol. (2015) 8:14693–700.
17. Hou B, Liu R, Qin Z, Luo D, Wang Q, Huang S. Oral Chinese herbal medicine as an adjuvant treatment for chemotherapy, or radiotherapy, induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. (2017) 2017:3432750. doi: 10.1155/2017/3432750
18. Zeng Y, Hu W, Jing P, Chen X, Wang Z, Wang L, et al. The regulation of ginsenoside Rg1 upon aging of bone marrow stromal cell contribute to delaying senescence of bone marrow mononuclear cells. Life Sci. (2018) 209:63–8. doi: 10.1016/j.lfs.2018.07.025
19. Höfer T, Rodewald HR. Differentiation-based model of hematopoietic stem cell functions and lineage pathways. Blood. (2018) 132:1106–13. doi: 10.1182/blood-2018-03-791517
20. Ow TJ, Thomas C, Fulcher CD, Chen J, López A, Reyna DE, et al. Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma. Laryngoscope. (2020) 130:2643–9. doi: 10.1002/lary.28441
21. Nebboh EE, Ufelle SA. Myeloprotective activity of crude methanolic leaf extract of Cassia occidentalis in cyclophosphamide-induced bone marrow suppression in Wistar rats. Adv Biomed Res. (2015) 4:5. doi: 10.4103/2277-9175.148285
22. Lu X, Li X, He Q, Gao J, Gao Y, Liu B, et al. MiR-142-3p regulates the formation and differentiation of hematopoietic stem cells in vetrbrates. Cell Res. (2013) 23:1356–68. doi: 10.1038/cr.2013.145
23. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. (2009) 136:215–33. doi: 10.1016/j.cell.2009.01.002
24. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al. HMGB1 release and reduct regulates autophagy and apoptosis in cancer cells. Oncogene. (2010) 29:5299–310. doi: 10.1038/onc.2010.261
25. Mandke P, Vasquez KM. Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses. DNA Repair. (2019) 83:102701. doi: 10.1016/j.dnarep.2019.102701
26. Guo X, He D, Zhang E, Chen J, Chen Q, Li Y, et al. HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair. J Exp Clin Cancer Res. (2018) 37:205. doi: 10.1186/s13046-018-0883-3
27. Xiao P, Liu WL. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Exp Pathol. (2015) 8:10800–7.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.630921/full#supplementary-material